Piracetam — Original Racetam Nootropic — Brain
The first synthetic nootropic ever developed, with cognitive enhancement claims. Approved in Europe; not FDA-approved in the US.
Overview
Piracetam (2-oxo-1-pyrrolidine acetamide) is the prototypical racetam nootropic, synthesized in 1964 by Corneliu Giurgea at UCB Pharmaceuticals in Belgium. Giurgea coined the term 'nootropic' specifically to describe piracetam's cognitive-enhancing properties. Piracetam is approved in many European countries for treatment of cognitive impairment, myoclonus, and vertigo, but it is not FDA-approved in the United States, where it occupies a regulatory gray area — not approved as a drug and removed from dietary supplement classification. Piracetam's mechanism involves modulation of AMPA and NMDA glutamate receptors, enhancement of membrane fluidity, and improvement of cerebrovascular blood flow. Clinical trials in elderly subjects with cognitive decline have shown modest improvements in memory, attention, and global cognitive function. A Cochrane review concluded there was 'not enough evidence to support the use of piracetam for dementia or cognitive impairment,' though individual studies showed positive trends. The drug has an exceptionally favorable safety profile — side effects are rare and typically mild (headache, insomnia, GI upset). Piracetam has virtually no toxicity, with an LD50 in rats greater than 10,000 mg/kg. Effective doses in clinical studies range from 2,400 to 4,800 mg daily, making it a high-volume supplement. It is the foundation from which all subsequent racetams (aniracetam, oxiracetam, phenylpiracetam, etc.) were derived.
Indications
- Approved (Europe): Cognitive disorders in elderly, cortical myoclonus, vertigo
- Not FDA-approved in United States
- Off-label: Cognitive enhancement in healthy individuals
- Off-label: Post-stroke cognitive rehabilitation
- Off-label: Dyslexia (limited evidence)
Mechanism of Action
Allosterically modulates AMPA-type glutamate receptors, enhancing excitatory neurotransmission and long-term potentiation (LTP)
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Piracetam | 800 mg | Three times daily (2,400 mg/day) | Standard European clinical dose |
| Piracetam | 1,600 mg | Three times daily (4,800 mg/day) | Higher clinical dose for cognitive impairment |
| Piracetam | 1,200-2,400 mg | Twice daily | Common nootropic community dosing |
Evidence Grade
GRADE B
Safety & Contraindications
- Exceptionally safe — very low toxicity (LD50 > 10,000 mg/kg in rats)
- Headache most common side effect (often attributed to choline depletion — may benefit from choline supplementation)
- Insomnia if taken too late in the day
- GI upset: nausea, diarrhea at high doses
- Weight gain rarely reported
- Not FDA-approved in US — regulatory status unclear
- Large pill burden (2,400-4,800 mg/day)